title: Clomipramine versus phenelzine in obsessive-compulsive disorder. A controlled clinical trial.
abstract: A double-blind clinical trial of clomipramine versus phenelzine was carried out on 30 patients suffering from DSM-III obsessive-compulsive disorder. The study period was 12 weeks, and the maximum doses used (from the fifth week on) were 225 mg/day for clomipramine (14 patients) and 75 mg/day for phenelzine (12 patients); four patients dropped out. Obsessive symptoms improved significantly in both drug groups, but there was no significant difference between groups. Depressive symptoms improved before obsessive ones.
authors.affiliation: Department of Psychiatry, Hospital de Prínceps d'Espanya, Barcelona, Spain.
authors.forename: J
authors.initials: J
authors.lastname: Vallejo
authors.forename: J
authors.initials: J
authors.lastname: Olivares
authors.forename: T
authors.initials: T
authors.lastname: Marcos
authors.forename: A
authors.initials: A
authors.lastname: Bulbena
authors.forename: J M
authors.initials: JM
authors.lastname: Menchón
mesh_terms: D000328:Adult; D002997:Clomipramine / Q000009:adverse effects / Q000627:therapeutic use*; D003866:Depressive Disorder / Q000188:drug therapy / Q000523:psychology; D003907:Dexamethasone; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D008297:Male; D009771:Obsessive-Compulsive Disorder / Q000188:drug therapy* / Q000523:psychology; D010555:Personality Inventory; D010624:Phenelzine / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D003907:Dexamethasone; D002997:Clomipramine; D010624:Phenelzine; D006854:Hydrocortisone